欧盟EMA药品数据库(European Medicines Agency Authorisation of Medicines DataBase)
商品名称Procomvax
适用类别Human
治疗领域Hepatitis B;Meningitis, Haemophilus;Immunization
通用名/非专利名称haemophilus B conjugate (meningococcal protein conjugate) and hepatitis B (recombinant) vaccine
活性成分polyribosylribitol phosphate from Haemophilus influenzae type b as PRP-OMPC;outer membrane protein complex of Neisseria meningitidis (outer membrane protein complex of the B11 strain of Neisseria meningitidis subgroup B);adsorbed hepatitis B surface antigen produced in recombinant yeast cells (Saccharomyces cerevisiae)
产品号EMEA/H/C/000231
患者安全信息No
许可状态Expired
ATC编码J07CA
是否额外监管No
是否仿制药或hybrid药物No
是否生物类似药No
是否附条件批准No
是否特殊情形No
是否加速审评No
是否罕用药No
上市许可日期1999/05/07
上市许可开发者/申请人/持有人Sanofi Pasteur MSD, SNC
人用药物治疗学分组Vaccines
兽用药物治疗学分组
欧盟委员会决定日期2007/12/11
修订号9
治疗适应症PROCOMVAX is indicated for vaccination against invasive disease caused by Haemophilus influenzae type b and against infection caused by all known subtypes of hepatitis B virus in infants 6 weeks to 15 months of age.
适用物种
兽用药物ATC编码
首次发布日期2007/12/11
最后更新日期2009/07/29
产品说明书https://www.ema.europa.eu/en/documents/product-information/procomvax-epar-product-information_en.pdf
公共评估报告https://www.ema.europa.eu/en/medicines/human/EPAR/procomvax
©2006-2025 DrugFuture->European Medicines Agency Authorisation of Medicines DataBase